Obiltoxaximab: First Global Approval

Drugs

Volumn 76, Issue 7, 2016, Pages 823-830

  Greig, Sarah L ^a  

^a Mairangi Bay   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DIPHENHYDRAMINE; DOXYCYCLINE; LEVOFLOXACIN; OBILTOXAXIMAB; ANTHRAX TOXIN; ANTITOXIN; BACTERIAL ANTIGEN; BACTERIAL TOXIN; MONOCLONAL ANTIBODY;

ALLERGIC REACTION; ANTHRAX; ANTIBODY RESPONSE; AREA UNDER THE CURVE; ARTICLE; BACILLUS ANTHRACIS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE ABSCESS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; POST EXPOSURE PROPHYLAXIS; PRURITUS; UPPER RESPIRATORY TRACT INFECTION; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; MACACA FASCICULARIS; PHASE 1 CLINICAL TRIAL (TOPIC); RABBIT; RESPIRATORY TRACT INFECTIONS; UNITED STATES;

ANIMALS; ANTHRAX; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; ANTITOXINS; BACILLUS ANTHRACIS; BACTERIAL TOXINS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG APPROVAL; HUMANS; MACACA FASCICULARIS; RABBITS; RESPIRATORY TRACT INFECTIONS; UNITED STATES;

EID: 84963728734     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-016-0577-0     Document Type: Article

References (41)

1. Chen Z, Moayeri M, Purcell R. Monoclonal antibody therapies against anthrax. Toxins. 2011;3(8):1004-19.
2. Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014;20(2):[article no. e130687].
3. US Food and Drug Administration. FDA approves new treatment for inhalation anthrax [media release]. 21 March 2016. http://www.fda.gov.
4. ® (obiltoxaximab) injection, for intravenous use: US prescribing Information. 2016. http://www.fda.gov. Accessed 23 Mar 2016.
5. Elusys Therapeutics Inc. Elusys CEO to testify on biodefense before house subcommittee [media release]. 21 Oct 2001. http://www.prnewswire.com.
6. Elusys Therapeutics Inc. Elusys submits IND to initiate human studies of anthrax drug; major milestone in company's development of Anthim [media release]. 28 Feb 2005. http://www.businesswire.com.
7. University of Texas at Austin. University of Texas at Austin, Southwest Foundation for Biomedical Research and Elusys Therapeutics test complete anthrax antidote in animals [media release]. 2 Oct 2002. http://www.engr.utexas.edu/news.
8. Elusys Therapeutics Inc. Elusys and US Army extend biodefense collaboration [media release]. 13 Dec 2006. http://prnewswire.com.
9. Elusys Therapeutics Inc. NIAID/BARDA awards Elusys a $12 million contract to further develop Anthim, the company's anthrax therapeutic [media release]. 25 Sep 2007. http://www.prnewswire.com.
10. ®, a new treatment for anthrax [media release]. 4 Jan 2010. http://www.elusys.com.
11. Elusys Therapeutics Inc. Elusys awarded additional $40.6 million under existing US government contract to fund advanced development of Anthim, a new treatment for anthrax [media release]. 4 Aug 2010. http://www.elusys.com.
12. Elusys Therapeutics Inc., Lonza. Elusys Therapeutics and Lonza extend manufacturing agreement for Anthim, a new anthrax treatment in late-stage development [media release]. 15 July 2010. http://www.elusys.com.
13. Elusys Therapeutics Inc. Elusys awarded $68 million contract to develop Anthim for intramuscular pre- and post-exposure prophylaxis of anthrax infection [media release]. 8 Sep 2011. http://www.elusys.com.
14. Elusys Therapeutics Inc. Elusys awarded additional $50.2 million under an exisiting US government contract to support final stages of development of ETI-204, for treatment of inhalational anthrax [media release]. 2 Aug 2012. http://www.elusys.com.
15. Elusys Therapeutics Inc. Elusys awarded additional $14.5 million under existing US government contracts supporting expanded human safety studies of ETI-204 for treatment of inhalational anthrax [media release]. 13 Sep 2012. http://www.elusys.com.
16. ® (obiltoxaximab) for treatment of inhalational anthrax [media release]. 6 Oct 2015. http://www.elusys.com.
17. ® (obiltoxaximab) for treatment of inhalational anthrax [media release]. 12 Nov 2015. http://www.elusys.com.
18. ® (obiltoxaximab) injection for the treatment and prophylaxis of inhalational anthrax [media release]. 21 Mar 2016. http://www.elusys.com.
19. US Patent and Trademark Office. US patent 8,093,360. 2012. http://ptft.uspto.gov. Accessed 12 Apr 2016.
20. Elusys Therapeutics Inc. Elusys receives notice of allowance from US Patent Office for methods of preventing or treating anthrax with ETI-204, an anti-anthrax antibody, via intramuscular injection [media release]. 10 Mar 2014. http://www.elusys.com.
21. Mohamed N, Clagett M, Li J, et al. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun. 2005;73(2):795-802.
22. Carpenter S, Serbina N, Yamamoto B, et al. Obiltoxaximab (ETI-204), a high affinity monoclonal antibody to protective antigen, rapidly reduces toxin levels and promotes bacterial clearance during Bacillus anthracis infection [abstract no. 211 (G)]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2015.
23. Serbina N, Shadiack A, O'Connor E, et al. Rabbit model of anthrax for exploring complementarity of antitoxin/antibiotic combination therapy on survival and development of adaptive immunity [abstract no. 101B]. In: Bacillus ACT - International Anthrax Conference, 2013.
24. Shadiack A, O'Connor E, Carpenter S, et al. Detection of endogenous anti-PA antibodies in anthrax-infected rabbits after treatment with ETI-204 [abstract no. 99C]. In: Bacillus ACT - International Anthrax Conference, 2013.
25. Serbina N, Shadiack A, O'Connor E, et al. Adaptive immunity in rabbits lethally challenged with Bacillus anthracis spores and treated with ETI-204: a monoclonal antibody against protective antigen [abstract no. 217 (G)]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2014.
26. Guttendorf R, Mondick J, Serbina N, et al. Animal to human dose translation under the animal rule - obiltoxaximab (ETI-204) case study [abstract no. 111 (G)]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2016.
27. Tang H, Mondick J, O'Connor E, et al. Pharmacokinetics of ETI-204, an anti-PA monoclonal antibody, in healthy and anthrax-infected rabbits and monkeys following IV and IM administration [abstract no. 100A]. In: Bacillus ACT - International Anthrax Conference, 2013.
28. Elusys Therapeutics Inc. Elusys Therapeutics presents efficacy results and other key findings on ETI-204 anthrax anti-toxin [media release]. 5 Sep 2013. http://www.elusys.com.
29. Nagy C, Mondick J, Czech A, et al. Safety, pharmacokinetics and immunogenicity of intramuscular (IM) administration of obiltoxaximab (ETI-204) to healthy humans [abstract no. 112 (G)]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2016.
30. Strout V, Casey L, Nardone L, et al. ETI-204, a monoclonal antibody with high affinity against protective antigen produced by anthrax, is well-tolerated and safe when administered alone or with ciprofloxacin in healthy volunteers [abstract no. B-584]. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2006.
31. Elusys Therapeutics Inc. Elusys announces results from three phase 3 safety studies of its anthrax anti-toxin, obiltoxaximab (ETI-204), in adult volunteers and completion of its phase 3 clinical development program [media release]. 22 Sep 2014, http://www.elusys.com.
32. Sanford D, Koo E, D'Alia G, et al. ETI-204 provides a dramatic improvement in survival at the onset of active anthrax disease and is well tolerated in nonhuman primates [abstract no. F1-3960]. In: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America - a joint meeting, 2008.
33. Casey LS, Porter J, Hulmes J, et al. ETI-204 anti-toxin monoclonal antibody treatment of active anthrax disease in rabbits [abstract no. 134B plus poster]. In: Bacillus ACT - International Anthrax Conference, 2009.
34. Yamamoto B, Serbina N, Carpenter S, et al. Obiltoxaximab (ETI-204) efficacy across a spectrum of disease severity in a trigger-to-treat cynomolgus monkey inhalational aerosol challenge model of anthrax [abstract no. 092 (G)]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2015.
35. Biron B, Beck K, Dyer D, et al. Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax. Antimicrob Agents Chemother. 2015;59(4):2206-14.
36. Serbina N, Stark G, Fisher A, et al. The use of meta-analysis approach to demonstrate added benefit of obiltoxaximab (ETI-204) in treatment of inhalational anthrax [abstract no. 110 (G)]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2016.
37. Yamamoto BJ, Shadiack AM, O'Connor EF, et al. Prophylactic efficacy of IM administered ETI-204 in an inhalational monkey aerosol challenge model of Bacillus anthracis [abstract no. 133]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2014.
38. Casey LS, Jones SM, Curtis K, et al. Intramuscular administration of a high-affinity anti-protective antigen MAb enhances post-exposure antibiotic efficacy against lethal B. anthracis spore challenge [abstract]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2006.
39. Casey L, Hulmes J, Middleton J, et al. Evaluation of the efficacy of ETI-204 when administered intramuscularly in a rabbit post-exposure spore challenge model [abstract no. 55 plus poster]. In: Bacillus ACT - International Anthrax Conference, 2011.
40. Serbina N, Shadiack A, O'Connor E, et al. Efficacy of intramuscularly (IM) administered anti-toxin in preventing inhalational anthrax-related mortality in the cynomolgus model of Bacillus anthracis infection [abstract no. 122 (G)]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2013.
41. Serbina N, Yamamoto B, Carpenter S, et al. Obiltoxaximab (ETI-204), demonstrates significant efficacy in primates when given intramuscularly after exposure to inhalational anthrax [abstract no. 209 (G) plus poster]. In: ASM Biodefense and Emerging Diseases Research Meeting, 2015.